



AndroGel® (testosterone) 1.62% – First-time generic

- On October 15, 2018, [Perrigo launched](#) an [AB-rated](#) generic version of AbbVie's [AndroGel \(testosterone\) 1.62%](#) metered dose pump and unit-dose packets.
 - Zydus Pharmaceuticals has also launched an authorized generic of AndroGel 1.62%.
- AndroGel 1.62% is indicated for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone:
 - Primary hypogonadism (congenital or acquired): testicular failure due to conditions such as cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, Klinefelter's syndrome, chemotherapy, or toxic damage from alcohol or heavy metals.
 - Hypogonadotropic hypogonadism (congenital or acquired): gonadotropin or luteinizing hormone-releasing hormone deficiency or pituitary-hypothalamic injury from tumors, trauma, or radiation.
- AndroGel 1.62% carries a boxed warning for secondary exposure to testosterone.
- According to IQVIA, U.S. sales for AndroGel 1.62% were approximately \$1 billion for the 12 months ending in August 2018.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2018 Optum, Inc. All rights reserved.